You searched for "AI"

42 results found

Artificial intelligence in bladder cancer diagnostics

Bladder cancer (BCa), ranking as the 10th most common cancer worldwide, poses a significant health burden with high morbidity and mortality [1]. Timely tumour detection and accurate evaluation are crucial for effective management, as the prognosis is dependent on the...

An interview with ChatGPT (3.5)

For this month’s Digital Review I explored the hype surrounding Chat Generative Pre-trained Transformer (GPT) from Open AI. The free version is still available at https://chat.openai.com/chat (ChatGPT 3.5) and was used in this article. At the time of writing this...

Urology Podcasts and NotebookLM

Podcasts, downloadable or streamable digital audio / video shows, have surged in popularity over the last five years due to the ubiquity of smartphones, high-speed mobile networks, and accessible content creation technology. They offer on-the-go access to expert discussions, clinical...

APAM (Association of Physicians of Great Britain and Ireland) 118th Annual Meeting 2025

Welcome to APAM 2025 - What Awaits? APAM 2025, the 118th Annual Meeting of the AoPGBI, will take place on 3–4 April 2025 at the Royal College of Physicians in London. This prestigious event will bring together leading clinicians, researchers,...

Announcing a new specialist distributor of medical devices for prostate cancer

Healthcare Supply Solutions are a new distributor focussed on medical devices for the diagnosis and management of Prostate Cancer.

Innovations in flexible ureteroscopy for renal calculi: a comprehensive review

This article has been verified for CPD. Click the button below to answer a few short questions and download a form to be included in your CPD folder. Flexible ureteroscopy (f-URS) has become a core modality in the treatment of...

Shared decision-making – minimising the mismatch

In Western countries, we are spoilt for choice in almost every aspect of our lives, but does that reflect also in healthcare? While we have taken some big strides towards shared decision-making with our patients, the age-old physician dominance remains...

Prostate Scotland appoints digital technology leader Peter Proud as new trustee

Prostate Scotland has appointed Peter Proud, Founder and CEO of Edinburgh-based digital technology company Forrit, to its Board of Trustees. Bringing more than 30 years of experience in digital transformation, data, and AI-driven innovation, Peter will support the charity’s work...

The case against omitting systematic biopsy in younger men

In this issue of European Urology, Al-Monajjed et al. report findings from the PROBASE trial, which evaluated prostate cancer (PC) detection in men aged 45–50 years with PSA ≥3ng/ml using both MRI-targeted biopsy (TBx) and systematic biopsy (SBx). Among 525...

Preoperative risk stratification of high-risk prostate cancer patients

High-risk prostate cancer (HRPCa) is associated with a significant risk of recurrence after radical treatment. While several classification systems exist, the D’Amico criteria – based on clinical T stage ≥T2c, prostate specific antigen (PSA) ≥20 ng/mL, or Gleason score (GS)...

Prostate cancer detection in younger men

Prostate cancer (PC) screening using prostate-specific antigen (PSA) testing with systematic biopsy (SBx) reduces mortality but risks overdiagnosis and unnecessary biopsies. Multiparametric MRI (mpMRI) enables MRI-targeted biopsy (TBx) of suspicious lesions and is now recommended before biopsy, although its role...

Supporting Patients Receiving Hormone Therapy: Introducing LiveWell

Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment, yet up to 30% of men experience significant long-term side effects affecting physical, metabolic, and psychological wellbeing. While there is strong evidence supporting exercise, lifestyle, and psychosocial interventions, access...